Impact of EGFR and p53 on Cancer Cell Response to Iressa
Author Information
Author(s): Magné N, Fischel J L, Dubreuil A, Formento P, Poupon M-F, Laurent-Puig P, Milano G
Primary Institution: Centre Antoine Lacassagne, Nice, France
Hypothesis
Does the status of EGFR, p53, and MAPK pathways influence the sensitivity of tumor cells to ZD1839 (Iressa)?
Conclusion
ZD1839 is effective against cancer cells with varying levels of EGFR, particularly those with higher expression, and its efficacy is not affected by p53 status.
Supporting Evidence
- ZD1839 showed a significant inverse correlation between IC50 values and EGFR levels (p=0.022).
- Cells with higher EGFR expression were more sensitive to ZD1839.
- p53 status did not influence the sensitivity to ZD1839.
- MAPK pathway status affected ZD1839 activity only in cells with high EGFR content.
Takeaway
This study looked at how different cancer cells respond to a drug called Iressa. It found that more of a certain protein (EGFR) makes the drug work better, but the gene p53 doesn't change how well the drug works.
Methodology
The study evaluated the antiproliferative activity of ZD1839 using a panel of human tumor cell lines, measuring EGFR expression, p53 status, and MAPK pathway activity.
Limitations
The study's conclusions may be limited by the specific cell lines used and the in vitro nature of the experiments.
Participant Demographics
The study involved human head and neck cancer cell lines and colon cancer cell lines with varying p53 statuses.
Statistical Information
P-Value
0.022
Statistical Significance
p=0.022
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website